Aptose Biosciences is a clinical-stage biotechnology company developing personalized therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research, coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.
No articles found.
Infinity Pharmaceuticals, Inc. is an innovative biopharmaceutical company dedicate...
Infinity Pharmaceuticals, Inc. is an innovative...
Syndax Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on ...
Syndax Pharmaceuticals, Inc. is a late-stage bi...
OptimizeRxÂŽ (OPRX) provides unique physician and consumer platforms and strategie...
OptimizeRxÂŽ (OPRX) provides unique physician a...
aTyrâs mission is to translate newly discovered biological pathways to develop i...
aTyrâs mission is to translate newly discover...
Sarepta Therapeutics is a U.S. commercial-stage biopharmaceutical company focused ...
Sarepta Therapeutics is a U.S. commercial-stage...
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates...
Merck KGaA, Darmstadt, Germany, a leading scien...
Genprex Inc is a U.S.-based clinical-stage gene therapy company. It is engaged in ...
Genprex Inc is a U.S.-based clinical-stage gene...
Turning Point Therapeutics is a clinical-stage precision oncology company with a p...
Turning Point Therapeutics is a clinical-stage ...
Join the National Investor Network and get the latest information with your interests in mind.